Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP: BAYRY )

6.800 +0.030 (+0.44%)
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Aktienges ADR

< Previous 1 2 3 4 5 6 Next >
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
Via Benzinga
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses? 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
22nd Century Group Reports Q1 Net Sales Of $9M, Up 33% YoY, Net Loss Also Grows
22nd Century Group, Inc. (NASDAQ: XXII) reported results for the first quarter ended March 31, 2022.. The company will host a live audio webcast on May 5, at 10:00 a.m. ET. 
Via Benzinga
Investment Strategy Monthly Insights, April 2022
After four decades of low inflation, developed economies are grappling with an inflation spike. 
Via Talk Markets
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
Merck Projects $10 Billion From Its Next Blockbuster Segment; Will It Measure Up?
Merck shares hit a six-month high Tuesday on the bullish projection. 
Via Investor's Business Daily
What Stocks Do Well During a Bear Market? 7 Picks for a Downturn
These are the best bear market stocks to invest in now. T, BG and CL are some great picks for investors looking to weather the storm. 
Via InvestorPlace
Recap: Bayer Q4 Earnings
Bayer (OTC:BAYRY) reported its Q4 earnings results on Tuesday, March 1, 2022 at 01:30 AM. Here's what investors need to know about the announcement. Earnings Bayer beat... 
Via Benzinga
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines." 
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer
Aveo Pharmaceuticals Inc (NASDAQ: AVEO) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022... 
Via Benzinga
Why Are Evotec Shares Trading Lower On Friday?
Bayer AG (OTC: BAYRY) has  
Via Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
Corporate Cannabis Takeover? Assessing 5 Big Industries Already At The Table
This article was originally published on The Bluntness, and ... 
Via Benzinga
Recursion, Bayer Expand Fibrosis Pact To Include Inferential Search Capabilities
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) expanded its existing strategic collaboration in fibrosis with Bayer AG (OTC: BAYRY). The expanded... 
Via Benzinga
Even Good Penny Stocks Like Senseonics Aren’t Always Profitable
Its latest implanted sensor lasts six months, but SENS stock faces competition from Dexcom, Abbott Labs and potentially one big name in tech. 
Via InvestorPlace
Bayer's Nubeqa Shows Prolonged Survival In Late-Stage Prostate Cancer Trial
Bayer AG (OTC: BAYRY) said a combination therapy, including its Nubeqa drug, was shown to prolong the lives of men who have metastatic prostate cancer in a clinical... 
Via Benzinga
Microsoft, Bayer Collaborate To Develop Digital Agricultural Tools, Capabilities
Microsoft Corp (NASDAQ: MSFT) and Bayer AG (OTC: BAYRY) (OTC: BAYZF) collaborated on new internet-based products aimed at helping farmers and industries... 
Via Benzinga
The Secret To Successful Investing In Biotech
Have you ever had a stock jump 30%, 50% or 100% in one day? 
Via Talk Markets
Agricultural Technology Companies Are Finding Themselves in a Global Race to Develop and Acquire New Intellectual Property
Image by AgriFORCE The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga... 
Via Benzinga
The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For... 
Via Benzinga
Exposures COVID-19 Product Safety
Here’s What Happens When You Beat The Market By 5% (And How To Do It)
See, the way Wall Street makes money has fundamentally shifted in recent years. So has the way information flows to individual investors. And today I want to show you how savvy stock pickers can profit... 
Via Talk Markets
I See Another “Chipotle Moment”
Lawsuits are terrible for business. They bring distractions, extra costs, and uncertainty. Big Tobacco knows this all too well. 
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer?
A biotech working in lung and blood diseases, as well as cancer, could be acquired. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.